Startups

nsave: $18 Million (Series A) Raised For Launching Investment Platform

By Amit Chowdhry ● Jan 13, 2025

nsave, a provider of compliant accounts abroad to people from countries with high inflation, announced launching an investment product, enabling people at risk of financial exclusion to protect and grow their wealth. The company also confirmed an $18 million Series A funding led by TQ Ventures with participation from Sequoia Capital, Y Combinator, ACE Ventures, and Proton Foundation to drive their growth.

RhyGaze: $86 Million (Series A) Raised To Develop Gene Therapies For Retinal Diseases

By Amit Chowdhry ● Jan 13, 2025

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, announced that it has raised a Series A funding round of $86 million. The funding round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital, and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed $11 million to an earlier seed round.

Kardigan: $300 Million Raised For Modernizing Cardiovascular Drug Development

By Amit Chowdhry ● Jan 13, 2025

Kardigan - a heart health company modernizing cardiovascular drug development - announced it launched with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve. The company also recently closed a $300 million Series A financing led by Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage.

Andreessen Horowitz Partnering With Lilly On $500 Million Biotech Ecosystem Venture Fund

By Amit Chowdhry ● Jan 13, 2025

Andreessen Horowitz (a16z) Bio + Health announced a newly formed and first-of-its-kind venture capital fund to fuel broader innovation in human health in partnership with Eli Lilly and Company (Lilly). The Biotech Ecosystem Venture Fund aims to drive transformative progress in healthcare by investing in therapeutic platforms and technology companies that can bring new medicines and disease treatments to improve patients’ lives.

Normunity: $75 Million (Series B) Raised For Broadening Pipeline Of Novel Anti-Cancer Therapies

By Amit Chowdhry ● Jan 13, 2025

Normunity, a biotechnology company creating novel anti-cancer therapies, announced today that it closed a Series B funding round of $75 million. The funding was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. And the Board of Directors will be expanded to include David Parry, PhD (Samsara), Sara Nayeem, MD (Enavate), and Marie-Clare Peakman, MD (Pfizer Ventures).

Tidal Cyber Buying Zero-Shot Security

By Amit Chowdhry ● Jan 13, 2025

Tidal Cyber, the Threat-Informed Defense company, announced the acquisition of Zero-Shot Security, the creator of an innovative artificial intelligence (AI) solution that simplifies and speeds the processing and analysis of threat intelligence.

Holly: AI-Based Government Hiring Platform Raises $2.2 Million

By Amit Chowdhry ● Jan 13, 2025

Holly, an AI-based platform modernizing government hiring, announced the closing of its $2.2 million oversubscribed pre-seed round, led by J2 Ventures with participation from Roble Ventures, Gaingels, and notable angel investors. And the funding will support Holly's platform as it works to solve the million-job government workforce vacancy crisis.

Tune Therapeutics: Over $175 Million (Series B) Raised For Advancing Field-Leading Epigenome Editing Programs

By Amit Chowdhry ● Jan 13, 2025

Leading epigenome editing company Tune Therapeutics announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation.